For example, clinical response to sapropterin dihydrochloride, an orally administered PAH enzyme cofactor analog that benefits a segment of PKU patients, is defined as a 30% decrease in blood Phe levels with treatment12. The gene discussed is PAH; the disease is phenylketonuria.